Catalyst Biosciences, Inc. – NASDAQ:CBIO
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 10 hours
Catalyst Biosciences stock price monthly change
+5.95%
month
Catalyst Biosciences stock price quarterly change
+75.30%
quarter
Catalyst Biosciences stock price yearly change
-12.02%
year
Catalyst Biosciences key metrics
Market Cap | 19.41M |
Enterprise value | 471.74K |
P/E | 1.25 |
EV/Sales | -0.59 |
EV/EBITDA | N/A |
Price/Sales | -10.79 |
Price/Book | 1.16 |
PEG ratio | 0.05 |
EPS | -1.37 |
Revenue | N/A |
EBITDA | -40.79M |
Income | -44.24M |
Revenue Q/Q | N/A |
Revenue Y/Y | -124.55% |
Profit margin | -860.96% |
Oper. margin | -789.42% |
Gross margin | 200.5% |
EBIT margin | -789.42% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCatalyst Biosciences stock price history
Catalyst Biosciences stock forecast
Catalyst Biosciences financial statements
| Dec 2022 | -794K | -40.45M | 5094.96% |
|---|---|---|---|
| Mar 2023 | 0 | 260K | |
| Jun 2023 | 0 | -2.47M | |
| Sep 2023 | 0 | -1.57M |
| 2025 | 3.17M | -638K | -20.09% |
|---|
Analysts Price target
Financials & Ratios estimates
Paying a dividend greater than earnings.
735.68%
Yield TTM
| Payout ratio | 772.31% |
|---|
| 2018 | |
|---|---|
| 2019 | |
| 2020 | |
| 2021 | |
| 2022 | 270.61% |
| Mar 2023 | 18750000 | 44.70M | 238.42% |
|---|---|---|---|
| Jun 2023 | 12394000 | 40.70M | 328.45% |
| Sep 2023 | 9964000 | 6.44M | 64.7% |
| Dec 2023 | 62394370 | 0 | 0% |
| Dec 2022 | -1.47M | 51K | 16K |
|---|---|---|---|
| Mar 2023 | -6.21M | 411K | -7.76M |
| Jun 2023 | -2.47M | 4.79M | -3.5M |
| Sep 2023 | -3.21M | 1M | -1.47M |
Catalyst Biosciences alternative data
| Sep 2023 | 7 |
|---|---|
| Oct 2023 | 7 |
| Nov 2023 | 7 |
| Dec 2023 | 7 |
| Jan 2024 | 7 |
| Feb 2024 | 7 |
| Mar 2024 | 7 |
| Apr 2024 | 7 |
| May 2024 | 7 |
| Jun 2024 | 7 |
| Jul 2024 | 7 |
Catalyst Biosciences other data
6.74%
-9.13%
of CBIO is owned by hedge funds
21
-11
2.12M
-2.86M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Oct 2023 | 8111111 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | GNI GROUP LTD. 10 percent owner | Series X Convertible Preferred Stock Warrant (Right to Buy) | 8,110,300 | N/A | N/A | ||
Purchase | GNI GROUP LTD. 10 percent owner | Series X Convertible Preferred Stock | 811 | N/A | N/A | ||
Purchase | BLOUSE GRANT E. officer: Chief Scientific Officer | Common Stock | 3,250 | $0.47 | $1,528 | ||
Purchase | MILLER SELINE E. officer: SVP Finance; Interim C.. | Common Stock | 3,250 | $0.47 | $1,528 | ||
Purchase | USMAN NASSIM officer: Presiden.. | Common Stock | 3,250 | $0.47 | $1,528 | ||
Purchase | USMAN NASSIM director, officer.. | Common Stock | 3,250 | $0.46 | $1,495 | ||
Purchase | MILLER SELINE E. officer: SVP Finance; Interim C.. | Common Stock | 3,250 | $0.46 | $1,495 | ||
Purchase | BLOUSE GRANT E. officer: Chief Scientific Officer | Common Stock | 3,250 | $0.46 | $1,495 | ||
Purchase | BLOUSE GRANT E. | Common Stock | 1,163 | $3.62 | $4,210 | ||
Purchase | LEVY HOWARD officer: Chief Medical Officer | Common Stock | 639 | $3.62 | $2,313 |
| Patent |
|---|
Grant Filling date: 19 Feb 2021 Issue date: 8 Mar 2022 |
Grant Filling date: 2 Nov 2018 Issue date: 21 Dec 2021 |
Application Filling date: 9 Jul 2021 Issue date: 18 Nov 2021 |
Application GENE THERAPY FOR HEMOPHILIA B WITH A CHIMERIC AAV CAPSID VECTOR ENCODING MODIFIED FACTOR IX POLYPEPTIDES Filling date: 28 Jan 2021 Issue date: 5 Aug 2021 |
Application Filling date: 16 Mar 2021 Issue date: 29 Jul 2021 |
Application Filling date: 3 Jan 2020 Issue date: 22 Jul 2021 |
Application Filling date: 19 Feb 2021 Issue date: 24 Jun 2021 |
Grant Filling date: 29 Mar 2016 Issue date: 20 Apr 2021 |
Grant Utility: Nucleic acid encoding modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use Filling date: 2 Jun 2020 Issue date: 23 Mar 2021 |
Application Filling date: 15 Aug 2020 Issue date: 11 Mar 2021 |
| Quarter | Transcript |
|---|---|
| Q3 2021 12 Nov 2021 | Q3 2021 Earnings Call Transcript |
| Q3 2014 5 Nov 2014 | Q3 2014 Earnings Call Transcript |
| Q2 2014 6 Aug 2014 | Q2 2014 Earnings Call Transcript |
| Q1 2014 7 May 2014 | Q1 2014 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Nassim Usman Ph.D. (1960) Pres, Chief Executive Officer & Director | $769,180 |
Dr. Howard Levy M.B.B.Ch., M.M.M., Ph.D. (1954) Consultant | $577,040 |
-
When is Catalyst Biosciences's next earnings date?
Unfortunately, Catalyst Biosciences's (CBIO) next earnings date is currently unknown.
-
Does Catalyst Biosciences pay dividends?
Yes, Catalyst Biosciences pays dividends and its trailing 12-month yield is 735.68% with 772% payout ratio.It means that the company is paying a dividend greater than earnings. The last Catalyst Biosciences stock dividend of $0.57 was paid on 19 Aug 2015.
-
How much money does Catalyst Biosciences make?
Catalyst Biosciences has a market capitalization of 19.41M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 89.18% to 794K US dollars.
-
What is Catalyst Biosciences's stock symbol?
Catalyst Biosciences, Inc. is traded on the NASDAQ under the ticker symbol "CBIO".
-
What is Catalyst Biosciences's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Catalyst Biosciences?
Shares of Catalyst Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Catalyst Biosciences's key executives?
Catalyst Biosciences's management team includes the following people:
- Dr. Nassim Usman Ph.D. Pres, Chief Executive Officer & Director(age: 65, pay: $769,180)
- Dr. Howard Levy M.B.B.Ch., M.M.M., Ph.D. Consultant(age: 71, pay: $577,040)
-
How many employees does Catalyst Biosciences have?
As Jul 2024, Catalyst Biosciences employs 7 workers.
-
When Catalyst Biosciences went public?
Catalyst Biosciences, Inc. is publicly traded company for more then 19 years since IPO on 12 Apr 2006.
-
What is Catalyst Biosciences's official website?
The official website for Catalyst Biosciences is catalystbiosciences.com.
-
Where are Catalyst Biosciences's headquarters?
Catalyst Biosciences is headquartered at 611 Gateway Boulevard, South San Francisco, CA.
-
How can i contact Catalyst Biosciences?
Catalyst Biosciences's mailing address is 611 Gateway Boulevard, South San Francisco, CA and company can be reached via phone at +65 08710761.
Catalyst Biosciences company profile:
Catalyst Biosciences, Inc.
catalystbiosciences.comExchange:
NASDAQ
Full time employees:
7
Industry:
Biotechnology
Sector:
Healthcare
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The company also develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. It has a strategic research collaboration with Mosaic Biosciences, Inc.; and license and collaboration agreement with Biogen International GmbH. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.
611 Gateway Boulevard
South San Francisco, CA 94080
South San Francisco, CA 94080
CIK: 0001124105
ISIN: US4037831033
CUSIP: 14888D208
